1. Home
  2. MCRB vs GLU Comparison

MCRB vs GLU Comparison

Compare MCRB & GLU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Seres Therapeutics Inc.

MCRB

Seres Therapeutics Inc.

HOLD

Current Price

$8.65

Market Cap

139.7M

Sector

Health Care

ML Signal

HOLD

Logo Gabelli Global Utility of Beneficial Ownership

GLU

Gabelli Global Utility of Beneficial Ownership

HOLD

Current Price

$21.27

Market Cap

119.8M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
MCRB
GLU
Founded
2010
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
139.7M
119.8M
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
MCRB
GLU
Price
$8.65
$21.27
Analyst Decision
Hold
Analyst Count
3
0
Target Price
$14.33
N/A
AVG Volume (30 Days)
93.5K
12.6K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
8.60%
EPS Growth
100.00
N/A
EPS
2.40
0.62
Revenue
$126,325,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$3.43
$34.47
Revenue Growth
1672.24
N/A
52 Week Low
$0.36
$14.07
52 Week High
$29.98
$21.69

Technical Indicators

Market Signals
Indicator
MCRB
GLU
Relative Strength Index (RSI) 26.09 75.73
Support Level $7.12 $17.78
Resistance Level $8.49 $21.69
Average True Range (ATR) 1.13 0.35
MACD -0.42 0.03
Stochastic Oscillator 5.42 87.14

Price Performance

Historical Comparison
MCRB
GLU

About MCRB Seres Therapeutics Inc.

Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

About GLU Gabelli Global Utility of Beneficial Ownership

Gabelli Global Utility & Income Trust is a non-diversified, closed-end management investment company. The Fund's objective is to seek a consistent level of after-tax total return. It predominantly invests in stocks of companies involved to a substantial extent in providing products, services, or equipment for the generation or distribution of electricity, gas, or water and infrastructure operations, and in equity securities including preferred securities of companies in other industries, in each case in such securities that are expected to pay periodic dividends.

Share on Social Networks: